非编码 RNA 在泛血管疾病中的研究进展

来源期刊：广州医药 | 122-132 发布时间：2026-02-20 收稿时间：2026/4/8 15:54:33 阅读量：257

作者：: 孙钰洺,

宫丽鸿,

肖福龙,

李越,

关键词：: 非编码RNA 泛血管疾病动脉粥样硬化; non-coding RNA panvascular diseases atherosclerosis

DOI：: 10.20223/j.cnki.1000-8535.2026.02.001

收稿时间：: 2025-04-07
修订日期：
接收日期：
引用总数：: 0

泛血管疾病（PVD）是一类以动脉粥样硬化为共同病理基础、累及心、脑、肾及外周血管系统的临床综合征, 具有多血管床共病特征, 发病率高、致残致死率大。非编码RNA（ncRNA）作为基因表达的重要调控因子, 在PVD的发生发展中发挥关键作用。微小RNA（miRNA）、长链非编码RNA（lncRNA）、环状RNA（circRNA）等ncRNA通过调节炎症反应、内皮功能、血管重塑、代谢稳态等多路径参与PVD的病理过程, 并展现出时空特异性和双向调控特征。最新研究揭示ncRNA在临床中的诊断预测及靶向干预潜力, 包括外泌体载体及circRNA递送系统等新策略。此外, 中医药通过调控ncRNA网络, 干预血瘀、痰浊等证型相关通路, 体现中西医结合治疗的系统优势。本文系统综述了ncRNA在PVD中的作用机制与研究进展, 强调其在精准诊疗与转化研究中的应用前景, 并指出未来需加强基础与临床协同、推进个体化干预策略的落地实施。

宫丽鸿 教授，中西医结合医学博士，中医学博士后，博士生导师，博士后合作导师。辽宁中医药大学附属医院心内科主任，国家中医药管理局心病重点专科、重点学科带头人，国家高水平中医药重点学科带头人，辽宁省“百千万人才”百人层次人才，“兴辽英才计划”医学名家，辽宁省领军人才，全国第四批名老中医药专家学术思想继承人。担任国家标准化心脏康复中心负责人、国家标准化体外反搏中心负责人、辽宁省中医老年心脑血管病重点实验室主任。主持国家级、省市级课题30余项。于国际期刊发表SCI（IF 5.6）、国家级核心期刊发表论文100余篇。出版著作10部，参与指南修订8部，申请国际和国内专利6项，获得授权发明专利6项。兼任中华中医药学会介入心脏病学分会副主任委员、中国中医药信息学会心脏康养分会副会长、中华中医药学会心血管病分会常委、中国中药协会心血管药物研究专委会常委、辽宁省中医药学会心血管分会主任委员、辽宁省中西医结合学会心血管病预防与康复专业委员会主任委员。

泛血管疾病（panvascular diseases，PVD）是一组以系统性血管病变为核心病理特征，累及心、脑、肾、外周动脉等器官的临床综合征。《2023年中国心血管健康与疾病报告》显示，我国心血管疾病（cardiovascular diseases，CVD）患者约3.3亿人，占总人口的24%，其中包括冠状动脉粥样硬化性心脏病（coronary heart disease，CHD）1 139万例、脑卒中1 300万例及外周血管疾病4 530万例，这在城乡地区导致了近40%的死亡率，造成了沉重的社会经济负担^［1］。值得注意的是，PVD常呈现多血管床共病特征：单血管病变患者1年主要不良心血管事件（majo r adverse cardiovascular events，MACE）发生率为2.2%，而多血管病变患者则升至9.2%，且多血管病变患者较单血管病变患者3年心血管死亡风险增加4%，MACE风险增加7%^［2］。动脉粥样硬化（atherosclerosis，AS）是PVD主要的病理基础，其可调控危险因素包括吸烟、高血压、糖尿病等^［3］。然而，传统危险因素控制后仍存在残余风险，提示需探索更深入的分子机制。研究表明，非编码RNA（non-coding RNA，ncRNA）虽不直接编码蛋白质，但通过调控基因表达参与多种病理过程^［4］。除肿瘤领域外，ncRNA在PVD中的作用也逐步得到揭示。例如，微小RNA（microRNA，miRNA）通过外泌体介导内皮损伤调控AS进展；在缺血性卒中中，长链非编码RNA（long non-coding RNA，lncRNA），可通过竞争性结合miRNA上调通道蛋白，加重脑组织缺血再灌注损伤^［5-6］。尽管相关研究已广泛开展，但目前仍缺乏系统性总结ncRNA在PVD中作用的最新综述。本综述将系统阐述ncRNA在主要PVD中的调控机制，为诊疗策略优化提供理论依据。

1 非编码 RNA 的分类与作用机制

ncRNA是一类不编码蛋白质的RNA分子，广泛参与基因表达的调控。根据其长度和功能，可分为多种类型，包括miRNA、lncRNA和环状RNA（circular RNA，circRNA）等。作为PVD的主要病理基础，动脉粥样硬化（atherosclerosis，AS）在CHD、CVD和PVD中均有显著表现^［7］。ncRNA在AS中扮演了多种角色，以下是其主要作用机制：（1）炎症反应，通过调节核因子κB（nuclear factor kappa-B，NF-κB）通路等信号通路调控炎症因子的表达，并影响血管内皮细胞（vascular endothelial cells，VECs）黏附过程，驱动血管炎症性疾病进展^［8］。（2）血管生成与内皮稳态，靶向血管内皮生长因子（vascular endothelial growth factor，VEGF）、Notch等通路促进血管新生，同时调控VECs增殖、凋亡及功能状态以维持^［9-10］。（3）氧化应激与代谢，通过调控氧化应激相关通路和脂代谢相关通路，如腺嘌呤核苷三磷酸（adenosine triphosphate，ATP）结合盒转运蛋白A1（ATP-binding cassette transporter A1，ABCA1）通路等，减轻内皮氧化损伤并参与AS形成^［11-12］。（4）血管重塑，介导血管平滑肌细胞（vascular smooth muscle cells，VSMCs）的表型转换，影响血管壁病理性重塑^［13］。

综上所述，ncRNA在AS的发生、发展中发挥了多维度的调控作用。这些机制共同揭示了ncRNA在PVD中的核心调控网络，为ncRNA在PVD中的诊断和治疗提供了新的理论依据。

2 非编码 RNA 在泛血管疾病中的研究进展

2.1 miRNA

miRNA是一类长度约22个核苷酸的ncRNA，通过结合信使RNA（messenger RNA，mRNA）3’非翻译区，调控基因表达。

2.1.1 冠心病 CHD的病理机制主要涉及AS、炎症反应、内皮功能障碍以及微血管功能障碍等多个方面。其中，AS是CHD的核心病理基础，其特征是动脉壁内脂质沉积、纤维组织增生和钙化，导致血管狭窄和血流受限。AS斑块的发生、进展和最终破裂是大多数心血管相关死亡的基础^［14］。

miRNA作为基因表达的关键调控因子，在AS病理进程中呈现细胞特异性的调控特征。其中miR-21和miR-155的双向调节机制尤为显著：在巨噬细胞中通过抑制KBTBD7/p38/NF-κB通路发挥抗炎作用^［15］，而在VSMCs则通过磷酸酶和紧张素同系物（phosphatase and tensin homologue，PTEN）/AKT/mTOR和Toll样受体（Toll-li ke receptors，TLR）/NF-κB通路促进增殖迁移，其作用方向受lncRNA CASC7等表观遗传调控因子的精密调控^［15-17］。值得注意的是，内皮祖细胞（endothelial progenitor cells，EPCs）外泌体递送的miR-21可通过恢复自噬流促进血管修复，提示其具有微环境依赖性的治疗潜力^［5］。miR-155在AS中的矛盾效应已形成学术共识：既通过B 细胞淋巴瘤6（B-cell lymphoma 6，BCL6）/趋化因子2（C-C motif chemokine ligand 2，CCL2）轴促进单核细胞浸润^［18］，又通过稳定p85α抑制ox-LDL诱导的细胞凋亡^［19］。但最新证据表明其过量表达可能通过NOD样受体热蛋白结构域相关蛋白3（NOD-like receptor thermal protein domain associated protein 3，NLRP3）炎性小体加重血管损伤，提示精确剂量调控的重要性^［20］。

临床转化研究揭示特定miRNA的诊断价值：（1）循环miR-21-5p和miR-146a-5p可作为急性冠脉综合征特异性标志物，而miR-17-5p降低是CHD的普适性指标^［21］；（2）miR-29a通过调控内皮NO合成与炎症平衡影响斑块稳定性，其表达水平与斑块类型存在显著相关性^［22］；（3）血清miR-203水平与冠状动脉病变严重程度呈正相关，可能成为多血管病变的预测因子^［23］。

综上，miRNA在AS及CHD中展现出时空特异性和双向调控特征，不仅深度参与病理进程，还具备潜在的诊断与治疗价值，为PVD的精准干预提供新路径。

2.1.2 脑血管疾病 CVD是一类影响大脑血管系统，导致脑组织供血异常的疾病，主要包括缺血性卒中、出血性卒中和脑血管畸形等，这些疾病是全球范围内死亡和神经功能障碍的主要原因之一^［24］。CVD的发生通常与血管壁的病理变化、血流动力学异常以及炎症反应密切相关。

Shi等^［25］发现，miR-155-5p的敲低通过调节双特异性磷酸酶14的表达来调节硫氧还蛋白相互作用蛋白/NLRP3通路进而减轻脑血管缺血再灌注炎症和细胞焦亡。Song等^［26］的研究表明，miR-124通过M2小胶质细胞分泌的细胞外囊泡（extracellular vesicles，EVs）递送至神经干细胞，激活适配蛋白相关激酶1/Notch通路，促进其增殖与分化进而驱动缺血性脑卒中后中枢神经修复。临床研究进一步揭示了miRNA表达水平与CVD的显著关联，如耿等人对比出血性脑卒中患者和对照组发现，出血性脑卒中患者血清miR-217-5p表达降低，且降低幅度与病情严重程度及预后不良程度呈负相关，这表明miR-217-5p可能通过抑制神经炎症以保护神经元，或成为卒中患者预后的独立保护因子及有效预测标志物^［27］。

2.1.3 外周血管疾病外周血管疾病是指心脏和脑以外的血管系统病变，主要累及动脉、静脉及淋巴管，以下肢AS最为常见。外周血管疾病的病理核心为血管狭窄或阻塞，导致组织缺血缺氧，临床表现为间歇性跛行、静息痛、躯体溃疡或坏疽等^［28］。ncRNA可通过多维度调控机制参与外周血管疾病血管再生。

通过靶向miRNA调控外周血管疾病进展已成为近年来的研究热点。miR-126家族通过下调磷脂酰肌醇-3-激酶调节亚基2等基因的表达，增强EPCs迁移与血管修复功能，改善血管损伤。例如，miR-126-5p通过核内结合Caspase-3抑制其活性，减少VECs凋亡并维持血管完整性^［28］。此外，Sieland等^［29］探究了外周血管疾病患者在不同强度步行运动中的miRNA表达变化，发现中等强度运动组miR-142-5p和miR-424-5p显著上调，其可能通过激活VEGF和mTOR信号通路调控VECs功能并促进血管侧支生成；而高强度运动虽显著增强代谢应激，却未引发miRNA适应性改变，提示miRNA介导的血管重塑机制并非依赖单纯运动强度驱动的代谢负荷。

2.1.4 肾脏相关疾病肾脏作为高灌注、微血管密集的器官，易受血流动力学异常与代谢紊乱的双重影响，因此成为PVD损伤的关键靶器官^［30］。ncRNA可通过表观遗传修饰、竞争性内源RNA（competitive endogenous RNA，ceRNA）网络及信号通路交互等方式，动态调控血管疾病中肾脏相关疾病的病理进程，并成为疾病发展的关键分子枢纽^［31］。

miRNA的双向调节作用在大血管病变的相关肾脏疾病中也有显著体现：例如梗阻性肾病中，Zhao等^［32］研究发现miR-21在输尿管梗阻诱导的肾积水模型中可由肾小管上皮细胞通过外泌体向成纤维细胞递送，并且靶向抑制PTEN并激活Akt通路，驱动成纤维细胞活化及肾纤维化进程。另外Farahani等^［33］进行的实验发现了8种与线粒体相关的miRNA （如miR-192、miR-320）转运在患有代谢综合征的肾动脉狭窄动物模型中会受到改变，其下调会通过负调控线粒体基因表达，导致线粒体肿胀、基质密度下降、氧化应激加剧、ATP生成减少，进而引发肾小管上皮细胞损伤、成纤维细胞活化及肾功能恶化。

在微血管病变方面，Peters等^［34］发现miR-103a-3p在糖尿病肾病（diabetic nephropathy，DN）模型中，靶向SNRK调控血管紧张素Ⅱ诱导的肾脏炎症和纤维化，其血清及尿液水平可作为早期诊断标志物。

高血压肾病也是重要的微血管性肾脏病变，Sequeira-Lopez等^［35］发现miR-106b-5p通过巨噬细胞维生素D受体缺失诱导分泌，进入肾小球旁细胞（JG细胞）后下调Pde3b和E2f1表达，激活cAMP通路促进肾素合成与释放，从而介导高血压及血管损伤，成为治疗肾素依赖性高血压和血管病变的潜在分子靶点。

2.2 lncRNA

lncRNA是一类长度超过200个核苷酸的ncRNA，通过表观遗传修饰、染色质重塑及转录/转录后调控等多层面参与生物学功能，并作为分子信号、诱饵、支架或miRNA海绵调控细胞分化、增殖与凋亡。

2.2.1 冠心病 lncRNA在AS中通过介导VECs的氧化应激、炎症和凋亡，驱动疾病起始^［36］。研究显示，转移相关肺腺癌转录本 1（metastasisassociated lung adenocarcinoma transcript 1，MALAT1）在VECs中高表达，通过吸附miR-22-3p激活NLRP3炎症小体，促进白细胞介素-1β和白细胞介素-18释放并激活NF-κB通路，加剧VECs炎症、通透性及凋亡，加速AS斑块进展^［37］；在急性心肌梗死中，MALAT1结合果蝇Zeste基因增强子同源物2（enhancer of Zeste homolog 2，EZH2）增强组蛋白H3K27me3修饰，抑制过氧化物酶体增殖物激活受体γ表达，加重炎症和胶原沉积，而抑制MALAT1则可能逆转此过程^［38］。除此以外，Xiang等^［39］还发现lncRNA Morrbid则通过促进单核/巨噬细胞募集来驱动斑块形成，其特异性敲除可显著抑制AS，提示其作为AS生物标志物及治疗靶点的潜力。

此外，Ghiasvand等^［40］进行的临床研究还表明，CAD患者外周血干细胞中lncRNA LASER的表达水平显著高于对照组，并与前蛋白转化酶枯草溶菌素9（proprotein convertase subtilisin/Kexin type 9，PCSK9）、低密度脂蛋白受体的基因表达及血浆PCSK9浓度呈强正相关，提示LASER可能通过协同调控PCSK9低密度脂蛋白受体通路参与脂代谢紊乱及AS进展。

综上，lncRNA作为多效性调控因子，通过表观遗传修饰、分子海绵等多机制调控血管内皮损伤中的氧化应激与炎症，为AS诊疗提供了从机制解析到靶向干预的新策略。

2.2.2 脑血管疾病 Zhang等^［6］的研究揭示了在体外氧糖剥夺模型中，脑微血管内皮细胞的MALAT1表达升高，而miR-126被抑制，敲低MALAT1可促进HBMECs增殖并减少凋亡。随后的荧光素酶实验也支持了MALAT1通过直接靶向并抑制miR-126削弱其激活PI3K/Akt通路的能力，从而加重氧糖剥夺诱导的细胞凋亡；而miR-126过表达可逆转这一损伤^［6］。此外，Fang等^［41］在研究脑组织缺血再灌注损伤时发现，lncRNA H19过表达能够抑制miR-107的表达，进而增加缺血区域的VEGF含量，促进ECs的有丝分裂。临床试验方面，Pan等^［42］进行体内实验发现，卒中后24 h小鼠脑内的核旁斑组装转录本 1（lncRNA nuclear paraspeckle assembly transcript 1，NEAT1）显著升高，敲低NEAT1可通过抑制脂滴团聚及过度自噬，改善脑灌注，减少梗死体积并促进神经功能恢复。

2.2.3 外周血管疾病 Tang等^［43］通过分析糖尿病模型及小鼠后肢缺血（hindlimb ischemia，HLI）模型研究发现，增强内皮一氧化氮表达的lncRNA（lncRNA enhancing endothelial nitric oxide expression，lncRNA LEENE）在糖尿病条件下表达受抑，其通过与RNA聚合酶II相关因子复合物亚基LEO1及转录因子MYC相互作用，促进促血管生成基因的转录激活，从而增强VECs功能、改善缺血组织血流恢复；且经实验验证了LEENE过表达可能逆转糖尿病小鼠的血管生成障碍。另外，Huang等^［44］通过体外EPCs实验及HLI小鼠实验发现，lncRNA H19通过竞争性结合miR-107解除其对FADD的抑制作用，从而抑制焦亡通路关键蛋白（如半胱天冬酶-1）的表达，增强EPCs的增殖、迁移与成管能力；随后的动物实验也支持过表达的H19的EPCs移植可显著促进HLI血流恢复，提示了H19/miR-107/FADD轴通过调控焦亡与血管新生改善EPCs功能，为外周血管疾病治疗提供新靶点。

2.2.4 肾脏相关疾病 lncRNA KIFAP3-5：1在DN患者血浆、db/db小鼠肾脏及高糖处理的肾小管细胞中显著下调，其通过靶向转录因子PRRX1的启动子区域负调控其表达，抑制肾小管上皮细胞上皮-间质转化及肾纤维化。过表达该分子可改善肾功能并延缓纤维化，血浆水平与肾功能指标显著相关，在随机森林模型中可提升DN预测准确性，有望作为诊断标志物或靶向PRRX1的治疗靶点^［45］。

在临床研究中，F u等发现lncRNA PR11-387H17.6在动脉粥样硬化性肾动脉狭窄患者的肾动脉组织及外周血白细胞中显著上调，揭示其具有作为诊断动脉粥样硬化性肾动脉狭窄的独立预测因子的潜质_［46］。在DN病理过程中，lncRNA AK044604通过抑制Sirt1/GSK3β信号轴降低足细胞自噬水平，加剧足细胞损伤及肾小球基底膜增厚，反之抑制lncRNA AK044604则恢复足细胞保护性标志物表达^［47］。此外，lncRNA SNHG14、lncRNA TUG1等lncRNA也能通过竞争性结合miRNA（如hsa-miR-107）调控胰岛素信号通路相关mRNA（如PPP1R3C、PRKAR2B、AKT3），参与高血压肾病进展^［48］。这些研究充分表明靶向lncRNA可能成为肾脏相关泛血管疾病的治疗新策略。

2.3 circRNA

circRNA是一类内源性ncRNA，具有独特的环状结构和稳定的表达特性。circRNA主要作为miRNA的海绵，即ceRNA，可以解除miRNA对mRNA的抑制并促进靶基因表达并通过circRNA-miRNA-mRNA调控网络在血管系统疾病的发生发展中起关键作用^［49］。

2.3.1 冠心病 Huang等^［50］发现circRNA USP36在ox-LDL处理的VECs中高表达，通过吸附miR-637，增强Wingless/Integrated（Wnt）4基因的表达，抑制VECs的增殖和迁移，加剧AS。并且，Chen等^［51］还发现，circRNA_ABCA1在AS小鼠模型中高表达，可吸附miR-140-3p，激活促分裂原活化蛋白激酶6轴加剧内皮损伤，并解除miR-140-3p对3-羟基-3-甲基戊二酰辅酶A还原酶/合成酶1的抑制，促进胆固醇合成，但其编码蛋白ABCA1促进胆固醇外排抑制泡沫细胞形成，提示其双重调控作用。此外，Pan等^［52］还指出，circARCN1在稳定型心绞痛/急性冠脉综合征患者的外周血单核细胞及颈动脉斑块中表达升高，其通过干扰人抗原R与USP31mRNA结合，抑制USP31介导的NF-κB激活，进而参与AS调控。

circRNA凭借其稳定环状结构及ceRNA网络核心作用，通过miRNA海绵机制动态调控血管稳态失衡与修复，其多向调控功能及与疾病风险的密切关联或为AS精准诊疗开辟了机制解析与靶向干预新路径。

2.3.2 脑血管疾病 Yang等^［53］通过研究血脑屏障（blood-brain barrier，BBB）损伤患者及小鼠大脑中动脉闭塞/再灌注模型发现，circ-FoxO3上调时，其通过结合mTOR/E2F1抑制mTORC1活性，进而促进自噬并清除细胞毒性聚集物，减轻缺血再灌注损伤中BBB的破坏；并且circ-FoxO3过表达有效缓解BBB通透性升高，维持BBB功能；而circ-FoxO3敲低将加剧损伤。在另一项研究中，在急性缺血性脑卒中中，锁定circSCMH1为关键分子，首次开发了“狂犬病病毒糖蛋白-circSCMH1-细胞外囊泡”脑靶向递送系统并模型验证，circ-SCMH1可直接结合转录因子MeCP2，解除其对神经修复基因的转录抑制，激活突触可塑性通路^［54］。这些研究在减少脑梗死面积，改善患者预后等方面提示了circRNA兼具CVD预后标志物与治疗靶点潜力，并经跨物种验证及多组学整合为circRNA疗法提供证据链。

2.3.3 外周血管疾病 circRNA在外周血管疾病中也展现了多重调控作用。例如，Chen等^［55］进行了体外和体内模型实验发现circ-ITCH通过募集TATA框结合蛋白相关因子15蛋白激活Nrf2信号通路，抑制铁死亡并改善人脐静脉VECs的生成，加速糖尿病足溃疡伤口愈合过程。此外Liu团队研究开发了一种封装编码VEGF-A的circRNA的球形纳米颗粒，并且经体外实验验证，该颗粒显著提升稳定性和VEGF-A持续表达的同时兼具生物相容性与低先天免疫原性^［56］。

综上，糖尿病足溃疡因局部微循环障碍及细胞外基质异常重塑，导致药物递送效率显著受限；circRNA凭借其高稳定性、多靶点调控特性及潜在载体功能，通过干预血管生成、炎症反应和纤维化进程，为突破药物递送屏障及促进伤口修复提供了创新性治疗策略。

2.3.4 肾脏相关疾病 Liu等^［57］聚焦DN中circ-0000953的作用及机制展开研究，发现在DN小鼠和患者肾组织中circ-0000953，在功能上，circ-0000953过表达可减轻蛋白尿、缓解肾损伤并促进足细胞自噬；机制上，circ-0000953通过靶向Mir665-3p-Atg4b调节自噬，且METTL3通过YTHDF2调控circ-0000953的表达和甲基化水平。综上，circ-0000953可作为DN潜在的生物标志物和治疗靶点。

2.4 其他类型的ncRNA

新一代测序表明，Piwi相互作用RNA在CVD中也表现出一定的表达模式，如piRNA-2106027通过调控肌钙蛋白1参与MI的发生和发展^［58］。而在小干扰RNA（small interfering RNA，siRNA）领域He等^［59］的研究发现，siRNA NORAD水平在CAD患者血浆中显著升高，其通过吸附miR-106a上调细胞周期蛋白D1促进VECs增殖迁移；与此相对，沉默NORAD诱导G1期停滞、ROS累积及铁死亡，提示了靶向NORAD/miR-106a/细胞周期蛋白D1轴或为AS治疗新策略。在临床研究方面，Ray等^［60］进行ORION-3研究发现，已实行常规降脂方案治疗但仍有AS伴或不伴低密度脂蛋白胆固醇升高的患者，治疗性inclisiran可显著降低低密度脂蛋白胆固醇和PCSK9浓度。

Zhan等^［61］通过大鼠脑缺血模型结合基因调控实验发现，Piwil2通过Janus激酶-信号转导与转录激活因子6通路上调表达，并协同piRNA/DNA甲基转移酶3A复合物增强环磷腺苷效应元件结合蛋白2启动子甲基化以抑制其转录；而低氧后处理可抑制Piwil2减少DNA甲基转移酶3A复合物活性，促进环磷腺苷效应元件结合蛋白2表达，进而恢复海马神经元树突结构与突触可塑性，改善受试体缺血后认知功能。

此外，Sun等^［62］研究发现在急性脑卒中患者中，snoRNA SNHG15通过激活IL-4-JAK信号转导与转录激活因子6信号通路，在与肿瘤坏死因子（tumor necrosis factor，TNF）受体相关因子2蛋白结合作用下，抑制K63泛素化并阻断MAPK/NF-κB炎症通路、减少TNF-α等促炎因子分泌和促进M2型巨噬细胞极化。

研究者发现，转运核糖核酸（ transfer ribonucleic acid，tRNA）来源的小RNA在缺氧、氧化应激等条件下抑制Wnt信号通路参与血管重塑，因此tRNA来源的小RNA可能通过调控该通路或相关机制，成为血管病理过程的潜在干预靶点^［63］。缺血再灌注或慢性缺氧是PVD的常见诱因，因此该研究方向有待进一步实验验证。

2.5 中西医研究进展

2.5.1 中医研究进展中医理论将CHD病机归结为“心脉痹阻”，其核心证型“痰浊” “血瘀”与ncRNA介导的炎症失衡、血管重构等病理过程存在分子层面的对应关系。中药调控呈现多维度干预特征：单药成分通过表观遗传修饰影响病理进程，如白藜芦醇激活Sirtuin1增强自噬缓解损伤，小檗碱通过mTOR/MAPK通路协调修复反应；复方制剂展现网络调控优势，如血瘀通胶囊通过lncRNA-CTB114C7.4/miR-3656/BCL2A1轴抑制细胞凋亡，印证中药“多靶点”干预特性^［64-65］。综上，中医药通过多靶点调控ncRNA的表达，抑制炎症、改善内皮功能、调节脂代谢，体现了针对CHD“整体调节”与“精准干预”的治疗优势。

在CVD方面，中医药通过ncRNA网络调控血管微环境的系统生物学优势体现在多维度干预机制：（1）单体成分如丹参酮IIA通过激活miR-124-5p/FoxO1信号轴，双重抑制神经炎症反应与细胞凋亡通路^［66］；（2）复方制剂如桃红四物汤则通过circ-Dnajc1/miR-27a-5p/C1qc轴等调控网络协同改善血脑屏障功能及神经元存活^［67］。这种多靶点调控特性通过动态平衡miRNA/lncRNA/circRNA的交互作用，实现抑制神经炎症级联、维持血管稳态、促进组织修复多种病理干预效应。

如Froldi等^［68］在外周血管疾病方面的研究显示，姜黄素可通过上调miRNA-93表达来增强EPCs增殖及毛细血管密度，从而显著改善后肢缺血小鼠的血流灌注与新血管形成。倪英群等^［69］建立了中医证候-血管损伤RNA关联模型，揭示lncRNA TUG1在气阴两虚夹瘀型糖尿病患者中表达异常增高。

在肾脏相关疾病方面，Zhang等^［70］发现铁皮石斛多糖通过抑制LncRNA XIST/TGF-β1通路延缓糖尿病肾病间质纤维化，其下调TGF-β1/Smad信号通路活性，将减少细胞外基质沉积，改善肾功能及病理损伤，为糖尿病肾病治疗提供了天然多糖策略。

综上所述，中医药通过构建中医病证关联RNA调控网络、解析经典复方多靶点分子模块等方式，诠释了“病－证－治”的多维互作机制，为PVD的精准干预提供了从“整体观”到“分子观”的创新性思维。

2.5.2 西医研究进展西医方面主要从心、肾等方面进行了研究。miR-135a-5p在高磷酸盐激活的TGFBR1/TAK1通路中表达降低，促进血管炎症及钙化，其通过抑制该通路，减少NF-κB/TNF-α释放并阻断血管平滑肌成骨分化。法尼醇X受体激活剂可上调miR-135a-5p表达，从而缓解血管炎性肾病的病理进程^［71］。

siRNA药物递送技术在近年来的临床研究中取得了重大突破。在心肌缺血再灌注损伤模型中，脂质纳米颗粒作为一种siRNA递送药物递送载体，可靶向富集于心脏梗死区域，并在再灌注阶段将功能性化学合成修饰信使核糖核酸（messenger RNA，mRNA）递送至目标细胞胞质内表达，该技术为基于RNA疗法（包括ncRNA与mRNA）的心脏再生治疗提供了关键递送策略，或为改善CHD后心肌修复开辟了新途径^［71］。

3 总结与展望

ncRNA在PVD诊疗中展现出多维突破。在机制研究层面，ncRNA通过ceRNA网络、表观遗传调控等途径阐明血管炎症、代谢异常及病理性重构的核心机制，衍生出RNA靶向药物、外泌体递送等精准干预策略。此外，中西医整合治疗也凸显了独特优势：通过多靶点协同调控，整合急慢性期管理，在缓解症状的同时降低药物不良反应及耐药风险；结合精准医学与辨证施治，构建基于中医证型-ncRNA关联的个体化治疗体系。基因编辑技术、智能递送系统及多组学整合分析正加速ncRNA临床转化进程，但目前仍面临递送效率与安全性验证等转化瓶颈。未来需强化基础-临床协同创新，建立标准化评估体系，推动PVD精准治疗实现跨越发展。

1、WONG%E2%80%83M%EF%BC%8CDAI%E2%80%83Y%EF%BC%8CGE%E2%80%83J%EF%BC%8EPan-vascular%E2%80%83disease%EF%BC%9AWhat%E2%80%83we%E2%80%83have%E2%80%83done%E2%80%83in%E2%80%83the%E2%80%83past%E2%80%83and%E2%80%83what%E2%80%83we%E2%80%83can%E2%80%83do%E2%80%83in%E2%80%83the%E2%80%83future%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECardiol%E2%80%83Plus%EF%BC%8C2024%EF%BC%8C9%EF%BC%881%EF%BC%89%EF%BC%9A1-5%EF%BC%8E

2、中国医师协会心血管内科医师分会．泛血管疾病抗栓治疗中国专家共识（2024版）［J］．中华医学杂志，2024，104（12）：906-923．

3、ZHOU%E2%80%83X%EF%BC%8CYU%E2%80%83L%EF%BC%8CZHAO%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EPanvascular%E2%80%83medicine%EF%BC%9AAn%E2%80%83%20emerging%E2%80%83%20discipline%E2%80%83%20focusing%E2%80%83%20on%E2%80%83atherosclerotic%E2%80%83diseases%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Heart%E2%80%83J%EF%BC%8C2022%EF%BC%8C43%EF%BC%8843%EF%BC%89%EF%BC%9A4528-4531%EF%BC%8E

4、ZHANG%E2%80%83Y%EF%BC%8CZHANG%E2%80%83J%EF%BC%8CXU%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8ERegulation%E2%80%83of%E2%80%83NcRNA-protein%E2%80%83binding%E2%80%83in%E2%80%83diabetic%E2%80%83foot%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83Pharmacother%EF%BC%8C2023%EF%BC%88160%EF%BC%89%EF%BC%9A114361%EF%BC%8E

5、KE%E2%80%83X%EF%BC%8CLIAO%E2%80%83Z%EF%BC%8CLUO%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EEndothelial%E2%80%83colony%02forming%E2%80%83cell-derived%E2%80%83exosomal%E2%80%83miR-21-5p%E2%80%83%20regulates%E2%80%83autophagic%E2%80%83flux%E2%80%83to%E2%80%83promote%E2%80%83vascular%E2%80%83endothelial%E2%80%83%20repair%E2%80%83by%E2%80%83inhibiting%E2%80%83SIPL1A2%E2%80%83in%E2%80%83atherosclerosis%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Commun%E2%80%83Signal%EF%BC%8C2022%EF%BC%8C20%EF%BC%881%EF%BC%89%EF%BC%9A30%EF%BC%8E

6、ZHANG%E2%80%83L%EF%BC%8CYANG%E2%80%83H%EF%BC%8CLI%E2%80%83W%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83MALAT1%E2%80%83%20promotes%E2%80%83OGD-induced%E2%80%83apoptosis%E2%80%83of%E2%80%83%20brain%E2%80%83microvascular%E2%80%83endothelial%E2%80%83cells%E2%80%83by%E2%80%83sponging%E2%80%83miR-126%E2%80%83to%E2%80%83repress%E2%80%83PI3K%2FAkt%E2%80%83signaling%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8ENeurochem%E2%80%83Res%EF%BC%8C2020%EF%BC%8C45%EF%BC%889%EF%BC%89%EF%BC%9A2091-2099%EF%BC%8E

7、中国医师协会中西医结合分会心血管专业委员会，中华中医药学会心血管病分会．动脉粥样硬化中西医防治专家共识（2021年）［J］．中国中西医结合杂志，2022，42（3）：287-293．

8、SOLTANI%E2%80%83S%EF%BC%8CZANDI%E2%80%83M%EF%BC%8EmiR-200c-3p%E2%80%83upregulation%E2%80%83and%E2%80%83ACE2%E2%80%83downregulation%E2%80%83via%E2%80%83bacterial%E2%80%83LPS%E2%80%83and%E2%80%83LTA%E2%80%83as%E2%80%83interesting%E2%80%83%20aspects%E2%80%83for%E2%80%83COVID-19%E2%80%83treatment%E2%80%83%20and%E2%80%83immunity%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Biol%E2%80%83Rep%EF%BC%8C2021%EF%BC%8C48%EF%BC%887%EF%BC%89%EF%BC%9A5809-5810%EF%BC%8E

9、HE%E2%80%83Z%EF%BC%8CZHONG%E2%80%83Y%EF%BC%8CREGMI%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8EExosomal%E2%80%83long%E2%80%83non-coding%E2%80%83RNA%E2%80%83TRPM2-AS%E2%80%83%20promotes%E2%80%83angiogenesis%E2%80%83in%E2%80%83gallbladder%E2%80%83cancer%E2%80%83through%E2%80%83interacting%E2%80%83with%E2%80%83PABPC1%E2%80%83to%E2%80%83activate%E2%80%83NOTCH1%E2%80%83signaling%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMol%E2%80%83Cancer%EF%BC%8C2024%EF%BC%8C23%EF%BC%881%EF%BC%89%EF%BC%9A65%EF%BC%8E

10、SRIRAM%E2%80%83K%EF%BC%8CLUO%E2%80%83Y%EF%BC%8CYUAN%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8EVascular%E2%80%83regulation%E2%80%83by%E2%80%83super%E2%80%83enhancer-Derived%E2%80%83LINC00607%EF%BC%BBJ%EF%BC%BD%EF%BC%8EFront%E2%80%83Cardiovasc%E2%80%83Med%EF%BC%8C2022%EF%BC%889%EF%BC%89%EF%BC%9A881916%EF%BC%8E

11、LU%E2%80%83X%EF%BC%8CYANG%E2%80%83B%EF%BC%8CYANG%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EMicroRNA-320b%E2%80%83modulates%E2%80%83cholesterol%E2%80%83efflux%E2%80%83and%E2%80%83atherosclerosis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Atheroscler%E2%80%83Thromb%EF%BC%8C2022%EF%BC%8C29%EF%BC%882%EF%BC%89%EF%BC%9A200-220%EF%BC%8E

12、%E2%80%83%20INFANTE-MEN%C3%89NDEZ%E2%80%83J%EF%BC%8CL%C3%93PEZ-PASTOR%E2%80%83A%E2%80%83R%EF%BC%8CGONZ%C3%81LEZ-L%C3%93PEZ%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83interplay%E2%80%83between%E2%80%83oxidative%E2%80%83%20stress%E2%80%83%20and%E2%80%83miRNAs%E2%80%83in%E2%80%83%20obesity-associated%E2%80%83hepatic%E2%80%83and%E2%80%83vascular%E2%80%83complications%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAntioxidants%EF%BC%88Basel%EF%BC%89%EF%BC%8C2020%EF%BC%8C9%EF%BC%887%EF%BC%89%EF%BC%9A607%EF%BC%8E

13、%E2%80%83%20YU%E2%80%83J%EF%BC%8CWANG%E2%80%83W%EF%BC%8CYANG%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83%20PSR%E2%80%83regulates%E2%80%83%20vascular%E2%80%83%20remodeling%E2%80%83through%E2%80%83%20encoding%E2%80%83%20a%E2%80%83novel%E2%80%83protein%E2%80%83arteridin%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirc%E2%80%83Res%EF%BC%8C2022%EF%BC%8C131%EF%BC%889%EF%BC%89%EF%BC%9A768-787%EF%BC%8E

14、王凤林，谢宝栋．microRNA在冠心病中的研究进展［J］．心血管康复医学杂志，2024，33（2）：252-255．

15、SOTHIVELR%E2%80%83V%EF%BC%8CHASAN%E2%80%83M%E2%80%83Y%EF%BC%8CMOHD%E2%80%83SAFFIAN%E2%80%83S%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8ERevisiting%E2%80%83miRNA-21%E2%80%83as%E2%80%83a%E2%80%83therapeutic%E2%80%83strategy%E2%80%83%0Afor%E2%80%83myocardial%E2%80%83infarction%EF%BC%9AA%E2%80%83systematic%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AJ%E2%80%83Cardiovasc%E2%80%83Pharmacol%EF%BC%8C2022%EF%BC%8C80%EF%BC%883%EF%BC%89%EF%BC%9A393-406%EF%BC%8E

16、%E2%80%83HUANG%E2%80%83R%EF%BC%8CHUANG%E2%80%83Y%EF%BC%8CZENG%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AUrsodeoxycholic%E2%80%83acid%E2%80%83inhibits%E2%80%83intimal%E2%80%83hyperplasia%EF%BC%8C%0Avascular%E2%80%83smooth%E2%80%83muscle%E2%80%83cell%E2%80%83excessive%E2%80%83proliferation%EF%BC%8C%0Amigration%E2%80%83%20via%E2%80%83%20blocking%E2%80%83%20miR-21%2FPTEN%2FAKT%2FmTOR%E2%80%83%0Asignaling%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Cycle%EF%BC%8C2020%EF%BC%8C19%0A%EF%BC%888%EF%BC%89%EF%BC%9A918-932%EF%BC%8E

17、%E2%80%83%20PEI%E2%80%83X%EF%BC%8CWEN%E2%80%83Y%EF%BC%8CCUI%E2%80%83F%EF%BC%8Cet%E2%80%83al%EF%BC%8ElncRNA%E2%80%83%20CASC7%E2%80%83%0Aregulates%E2%80%83pathological%E2%80%83progression%E2%80%83of%E2%80%83ox-LDL%02stimulated%E2%80%83%20atherosclerotic%E2%80%83%20cell%E2%80%83models%E2%80%83%20via%E2%80%83%20sponging%E2%80%83%0AmiR-21%E2%80%83and%E2%80%83regulating%E2%80%83PI3K%2FAkt%E2%80%83and%E2%80%83TLR4%2FNF-%CE%BAB%E2%80%83%0Asignaling%E2%80%83pathways%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAging%EF%BC%88Albany%E2%80%83NY%EF%BC%89%EF%BC%8C%0A2021%EF%BC%8C13%EF%BC%8823%EF%BC%89%EF%BC%9A25408-25425%EF%BC%8E

18、LIU%E2%80%83Y%EF%BC%8CHE%E2%80%83M%EF%BC%8CYUAN%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8ENeutrophil%02membrane-coated%E2%80%83%20biomineralized%E2%80%83%20metal-organic%E2%80%83%0Aframework%E2%80%83nanoparticles%E2%80%83for%E2%80%83atherosclerosis%E2%80%83treatment%E2%80%83%0Aby%E2%80%83targeting%E2%80%83gene%E2%80%83silencing%EF%BC%BBJ%EF%BC%BD%EF%BC%8EACS%E2%80%83Nano%EF%BC%8C2023%EF%BC%8C%0A17%EF%BC%888%EF%BC%89%EF%BC%9A7721-7732%EF%BC%8E

19、RUAN%E2%80%83Z%EF%BC%8CCHU%E2%80%83T%EF%BC%8CWU%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EmiR-155%E2%80%83inhibits%E2%80%83%0Aoxidized%E2%80%83low-density%E2%80%83lipoprotein-induced%E2%80%83%20apoptosis%E2%80%83%0Ain%E2%80%83different%E2%80%83cell%E2%80%83models%E2%80%83by%E2%80%83targeting%E2%80%83the%E2%80%83p85%CE%B1%2FAKT%E2%80%83%0Apathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Physiol%E2%80%83Biochem%EF%BC%8C2020%EF%BC%8C76%0A%EF%BC%882%EF%BC%89%EF%BC%9A329-343%EF%BC%8E

20、%E2%80%83%20PENG%E2%80%83Q%EF%BC%8CYIN%E2%80%83R%EF%BC%8CZHU%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EmiR-155%E2%80%83activates%E2%80%83%0Athe%E2%80%83NLRP3%E2%80%83inflammasome%E2%80%83by%E2%80%83regulating%E2%80%83the%E2%80%83MEK%2FERK%2F%0ANF-%CE%BAB%E2%80%83pathway%E2%80%83in%E2%80%83carotid%E2%80%83atherosclerotic%E2%80%83plaques%E2%80%83in%E2%80%83%0AApoE-%2F-%E2%80%83mice%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Physiol%E2%80%83Biochem%EF%BC%8C2022%EF%BC%8C78%0A%EF%BC%882%EF%BC%89%EF%BC%9A365-375%EF%BC%8E

21、ZHELANKIN%E2%80%83A%E2%80%83V%EF%BC%8CSTONOGINA%E2%80%83D%E2%80%83A%EF%BC%8CVASILIEV%E2%80%83S%E2%80%83%0AV%EF%BC%8Cet%E2%80%83al%EF%BC%8ECirculating%E2%80%83extracellular%E2%80%83miRNA%E2%80%83analysis%E2%80%83in%E2%80%83%0Apatients%E2%80%83with%E2%80%83stable%E2%80%83CAD%E2%80%83and%E2%80%83acute%E2%80%83coronary%E2%80%83syndromes%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomolecules%EF%BC%8C2021%EF%BC%8C11%EF%BC%887%EF%BC%89%EF%BC%9A962%EF%BC%8E

22、林红丽，张雪菲，彭慧，等．microRNA-29a与冠心病心绞痛患者血管内皮损伤及斑块不稳定性的相关性［J］．中国现代医学杂志，2023，33（17）：84-88．

23、POLYAKOVA%E2%80%83E%E2%80%83A%EF%BC%8CZARAISKII%E2%80%83M%E2%80%83I%EF%BC%8CMIKHAYLOV%E2%80%83%0AE%E2%80%83N%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83%20of%E2%80%83%20myocardial%E2%80%83%20and%E2%80%83%20serum%E2%80%83%0AmiRNA%E2%80%83%20expression%E2%80%83%20patterns%E2%80%83%20with%E2%80%83the%E2%80%83%20presence%E2%80%83%20and%E2%80%83%0Aextent%E2%80%83of%E2%80%83coronary%E2%80%83artery%E2%80%83disease%EF%BC%9AA%E2%80%83cross-sectional%E2%80%83%0Astudy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Cardiol%EF%BC%8C2021%EF%BC%88322%EF%BC%89%EF%BC%9A9-15%EF%BC%8E

24、%E2%80%83%20HAN%E2%80%83Y%E2%80%83C%EF%BC%8CXIE%E2%80%83H%E2%80%83Z%EF%BC%8CLU%E2%80%83B%EF%BC%8Cet%E2%80%83al%EF%BC%8EEffect%E2%80%83%20of%E2%80%83%0Aberberine%E2%80%83on%E2%80%83global%E2%80%83modulation%E2%80%83of%E2%80%83lncRNAs%E2%80%83and%E2%80%83mRNAs%E2%80%83%0Aexpression%E2%80%83profiles%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83stable%E2%80%83coronary%E2%80%83heart%E2%80%83%0Adisease%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Genomics%EF%BC%8C2022%EF%BC%8C23%EF%BC%881%EF%BC%89%EF%BC%9A%0A400%EF%BC%8E

25、SHI%E2%80%83Y%EF%BC%8CLI%E2%80%83Z%EF%BC%8CLI%E2%80%83K%EF%BC%8Cet%E2%80%83al%EF%BC%8EmiR-155-5p%E2%80%83accelerates%E2%80%83%0Acerebral%E2%80%83ischemia-reperfusion%E2%80%83inflammation%E2%80%83injury%E2%80%83and%E2%80%83%0Acell%E2%80%83pyroptosis%E2%80%83via%E2%80%83DUSP14%2F%E2%80%83TXNIP%2FNLRP3%E2%80%83pathway%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EActa%E2%80%83Biochim%E2%80%83Pol%EF%BC%8C2022%EF%BC%8C69%EF%BC%884%EF%BC%89%EF%BC%9A787-%0A793%EF%BC%8E

26、%E2%80%83%20SONG%E2%80%83Y%EF%BC%8CSHI%E2%80%83R%EF%BC%8CLIU%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EM2%E2%80%83%20microglia%E2%80%83%0Aextracellular%E2%80%83vesicle%E2%80%83miR-124%E2%80%83regulates%E2%80%83neural%E2%80%83stem%E2%80%83cell%E2%80%83%0Adifferentiation%E2%80%83in%E2%80%83ischemic%E2%80%83stroke%E2%80%83via%E2%80%83AAK1%2FNOTCH%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EStroke%EF%BC%8C2023%EF%BC%8C54%EF%BC%8810%EF%BC%89%EF%BC%9A2629-2639%EF%BC%8E

27、耿炜，周涛，李晓鹏，等．出血性脑卒中患者血清miR-217-5p表达及临床意义［J］．心脑血管病防治，2023，23（11）：18-22，31．

28、%E2%80%83%20MAZZOLAI%E2%80%83L%EF%BC%8CTEIXIDO-TURA%E2%80%83G%EF%BC%8CLANZI%E2%80%83S%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8E2024%E2%80%83ESC%E2%80%83Guidelines%E2%80%83for%E2%80%83the%E2%80%83management%E2%80%83%20of%E2%80%83%0Aperipheral%E2%80%83arterial%E2%80%83and%E2%80%83aortic%E2%80%83diseases%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Heart%E2%80%83%0AJ%EF%BC%8C2024%EF%BC%8C45%EF%BC%8836%EF%BC%89%EF%BC%9A3538-3700%EF%BC%8E

29、SIELAND%E2%80%83J%EF%BC%8CNIEDERER%E2%80%83D%EF%BC%8CENGEROFF%E2%80%83T%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EChanges%E2%80%83in%E2%80%83miRNA%E2%80%83%20expression%E2%80%83in%E2%80%83%20patients%E2%80%83with%E2%80%83%0Aperipheral%E2%80%83arterial%E2%80%83vascular%E2%80%83disease%E2%80%83during%E2%80%83moderate-%E2%80%83%0Aand%E2%80%83vigorous-intensity%E2%80%83physical%E2%80%83activity%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83J%E2%80%83%0AAppl%E2%80%83Physiol%EF%BC%8C2023%EF%BC%8C123%EF%BC%883%EF%BC%89%EF%BC%9A645-654%EF%BC%8E

30、BORRI%E2%80%83M%EF%BC%8CJACOBS%E2%80%83M%E2%80%83E%EF%BC%8CCARMELIET%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AEndothelial%E2%80%83dysfunction%E2%80%83in%E2%80%83the%E2%80%83aging%E2%80%83kidney%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAm%E2%80%83J%E2%80%83Physiol%E2%80%83Renal%E2%80%83Physiol%EF%BC%8C2025%EF%BC%8C328%EF%BC%884%EF%BC%89%EF%BC%9A%0AF542-F562

31、ZHANG%E2%80%83C%EF%BC%8CZHAO%E2%80%83H%EF%BC%8CYAN%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83evf-%0A2%E2%80%83exacerbates%E2%80%83podocyte%E2%80%83injury%E2%80%83in%E2%80%83diabetic%E2%80%83nephropathy%E2%80%83%0Aby%E2%80%83inducing%E2%80%83%20cell%E2%80%83%20cycle%E2%80%83%20re-entry%E2%80%83%20and%E2%80%83inflammation%E2%80%83%0Athrough%E2%80%83distinct%E2%80%83mechanisms%E2%80%83triggered%E2%80%83by%E2%80%83hnRNPU%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAdv%E2%80%83Sci%EF%BC%88Weinh%EF%BC%89%EF%BC%8C2024%EF%BC%8C11%EF%BC%8847%EF%BC%89%EF%BC%9A%0Ae2406532%EF%BC%8E

32、ZHAO%E2%80%83S%EF%BC%8CLI%E2%80%83W%EF%BC%8CYU%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8EExosomal%E2%80%83miR-21%E2%80%83from%E2%80%83tubular%E2%80%83cells%E2%80%83contributes%E2%80%83to%E2%80%83%20renal%E2%80%83fibrosis%E2%80%83%20by%E2%80%83%0Aactivating%E2%80%83fibroblasts%E2%80%83via%E2%80%83targeting%E2%80%83PTEN%E2%80%83in%E2%80%83obstructed%E2%80%83%0Akidneys%EF%BC%BBJ%EF%BC%BD%EF%BC%8ETheranostics%EF%BC%8C2021%EF%BC%8C11%EF%BC%8818%EF%BC%89%EF%BC%9A%0A8660-8673%EF%BC%8E

33、%E2%80%83%20FARAHANI%E2%80%83R%E2%80%83A%EF%BC%8CZHU%E2%80%83X%E2%80%83Y%EF%BC%8CTANG%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMetabolic%E2%80%83syndrome%E2%80%83alters%E2%80%83the%E2%80%83cargo%E2%80%83of%E2%80%83mitochondria%02related%E2%80%83microRNAs%E2%80%83in%E2%80%83swine%E2%80%83mesenchymal%E2%80%83stem%E2%80%83cell%02derived%E2%80%83extracellular%E2%80%83vesicles%EF%BC%8Cimpairing%E2%80%83their%E2%80%83capacity%E2%80%83%0Ato%E2%80%83repair%E2%80%83the%E2%80%83stenotic%E2%80%83kidney%EF%BC%BBJ%EF%BC%BD%EF%BC%8EStem%E2%80%83Cells%E2%80%83Int%EF%BC%8C%0A2020%EF%BC%882020%EF%BC%89%EF%BC%9A8845635%EF%BC%8E

34、PETERS%E2%80%83L%E2%80%83J%E2%80%83F%EF%BC%8CFLOEGE%E2%80%83J%EF%BC%8CBIESSEN%E2%80%83E%E2%80%83A%E2%80%83L%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EMicroRNAs%E2%80%83in%E2%80%83chronic%E2%80%83kidney%E2%80%83disease%EF%BC%9AFour%E2%80%83%0Acandidates%E2%80%83for%E2%80%83clinical%E2%80%83application%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83%20J%E2%80%83Mol%E2%80%83%0ASci%EF%BC%8C2020%EF%BC%8C21%EF%BC%8818%EF%BC%89%EF%BC%9A6547%EF%BC%8E

35、%E2%80%83%20SEQUEIRA-LOPEZ%E2%80%83M%E2%80%83L%E2%80%83S%EF%BC%8CGOMEZ%E2%80%83R%E2%80%83A%EF%BC%8ERenin%E2%80%83%0Acells%EF%BC%8Cthe%E2%80%83kidney%EF%BC%8Cand%E2%80%83hypertension%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirc%E2%80%83%0ARes%EF%BC%8C2021%EF%BC%8C128%EF%BC%887%EF%BC%89%EF%BC%9A887-907%EF%BC%8E

36、%E2%80%83%20DU%E2%80%83J%EF%BC%8CHAN%E2%80%83R%EF%BC%8CLI%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8ELncRNA%E2%80%83HCG11%2FmiR-%0A26b-5p%2FQKI5%E2%80%83feedback%E2%80%83loop%E2%80%83reversed%E2%80%83high%E2%80%83glucose%02induced%E2%80%83%20proliferation%E2%80%83and%E2%80%83angiogenesis%E2%80%83inhibition%E2%80%83of%E2%80%83%0AHUVECs%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Cell%E2%80%83Mol%E2%80%83Med%EF%BC%8C2020%EF%BC%8C24%EF%BC%8824%EF%BC%89%EF%BC%9A%0A14231-14246%EF%BC%8E

37、%E2%80%83GONG%E2%80%83Y%E2%80%83P%EF%BC%8CZHANG%E2%80%83Y%E2%80%83W%EF%BC%8CSU%E2%80%83X%E2%80%83Q%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AInhibition%E2%80%83of%E2%80%83long%E2%80%83noncoding%E2%80%83RNA%E2%80%83MALAT1%E2%80%83suppresses%E2%80%83%0Ahigh%E2%80%83glucose-induced%E2%80%83apoptosis%E2%80%83and%E2%80%83inflammation%E2%80%83in%E2%80%83%0Ahuman%E2%80%83umbilical%E2%80%83vein%E2%80%83endothelial%E2%80%83cells%E2%80%83by%E2%80%83suppressing%E2%80%83%0Athe%E2%80%83NF-%CE%BAB%E2%80%83signaling%E2%80%83pathway%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiochem%E2%80%83Cell%E2%80%83%0ABiol%EF%BC%8C2020%EF%BC%8C98%EF%BC%886%EF%BC%89%EF%BC%9A669-675%EF%BC%8E

38、CHANG%E2%80%83F%EF%BC%8CWANG%E2%80%83C%EF%BC%8CZHENG%E2%80%83P%EF%BC%8Cet%E2%80%83al%EF%BC%8EMalat1%E2%80%83%0Apromotes%E2%80%83%20macrophage-associated%E2%80%83inflammation%E2%80%83%20by%E2%80%83%0Aincreasing%E2%80%83PPAR-%CE%B3%E2%80%83%20methylation%E2%80%83through%E2%80%83%20binding%E2%80%83%0Ato%E2%80%83EZH2%E2%80%83in%E2%80%83acute%E2%80%83myocardial%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83%0AImmunopharmacol%EF%BC%8C2023%EF%BC%88123%EF%BC%89%EF%BC%9A110695%EF%BC%8E

39、%E2%80%83%20XIANG%E2%80%83D%EF%BC%8CJIANG%E2%80%83L%EF%BC%8CYUAN%E2%80%83Q%EF%BC%8Cet%E2%80%83al%EF%BC%8ELeukocyte%02specific%E2%80%83morrbid%E2%80%83promotes%E2%80%83leukocyte%E2%80%83differentiation%E2%80%83and%E2%80%83%0Aatherogenesis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EResearch%EF%BC%88Wash%E2%80%83D%E2%80%83C%EF%BC%89%EF%BC%8C2023%0A%EF%BC%886%EF%BC%89%EF%BC%9A0187%EF%BC%8E

40、%E2%80%83%20GHIASVAND%E2%80%83T%EF%BC%8CKARIMI%E2%80%83J%EF%BC%8CKHODADADI%E2%80%83I%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EThe%E2%80%83interplay%E2%80%83of%E2%80%83LDLR%EF%BC%8CPCSK9%EF%BC%8Cand%E2%80%83lncRNA-%E2%80%83%0ALASER%E2%80%83genes%E2%80%83expression%E2%80%83in%E2%80%83coronary%E2%80%83artery%E2%80%83disease%EF%BC%9A%0AImplications%E2%80%83for%E2%80%83therapeutic%E2%80%83interventions%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AProstaglandins%E2%80%83Other%E2%80%83Lipid%E2%80%83Mediat%EF%BC%8C2025%EF%BC%88177%EF%BC%89%EF%BC%9A%0A106969%EF%BC%8E

41、FANG%E2%80%83H%EF%BC%8CLI%E2%80%83H%E2%80%83F%EF%BC%8CPAN%E2%80%83Q%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83noncoding%E2%80%83%0ARNA%E2%80%83H19%E2%80%83overexpression%E2%80%83protects%E2%80%83against%E2%80%83hypoxic-ischemic%E2%80%83brain%E2%80%83damage%E2%80%83by%E2%80%83inhibiting%E2%80%83miR-107%E2%80%83and%E2%80%83up%02regulating%E2%80%83vascular%E2%80%83endothelial%E2%80%83growth%E2%80%83factor%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAm%E2%80%83J%E2%80%83Pathol%EF%BC%8C2021%EF%BC%8C191%EF%BC%883%EF%BC%89%EF%BC%9A503-514%EF%BC%8E

42、%E2%80%83%20PAN%E2%80%83Y%EF%BC%8CXIN%E2%80%83W%EF%BC%8CWEI%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8EKnockdown%E2%80%83%20of%E2%80%83%0ANEAT1%E2%80%83prevents%E2%80%83post-stroke%E2%80%83lipid%E2%80%83droplet%E2%80%83agglomeration%E2%80%83%0Ain%E2%80%83microglia%E2%80%83by%E2%80%83regulating%E2%80%83autophagy%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Mol%E2%80%83%0ALife%E2%80%83Sci%EF%BC%8C2024%EF%BC%8C81%EF%BC%881%EF%BC%89%EF%BC%9A30%EF%BC%8E

43、%E2%80%83%20TANG%E2%80%83X%EF%BC%8CLUO%E2%80%83Y%EF%BC%8CYUAN%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83noncoding%E2%80%83%0ARNA%E2%80%83%20LEENE%E2%80%83%20promotes%E2%80%83%20angiogenesis%E2%80%83%20and%E2%80%83ischemic%E2%80%83%0Arecovery%E2%80%83in%E2%80%83diabetes%E2%80%83models%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Clin%E2%80%83Invest%EF%BC%8C%0A2023%EF%BC%8C133%EF%BC%883%EF%BC%89%EF%BC%9Ae161759%EF%BC%8E

44、HUANG%E2%80%83L%EF%BC%8CYE%E2%80%83Y%EF%BC%8CSUN%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EL%20n%20cRNA%E2%80%83%0AH19%2FmiR-107%E2%80%83%20regulates%E2%80%83%20endothelial%E2%80%83%20progenitor%E2%80%83%20cell%E2%80%83%0Apyroptosis%E2%80%83and%E2%80%83promotes%E2%80%83flow%E2%80%83recovery%E2%80%83of%E2%80%83lower%E2%80%83extremity%E2%80%83%0Aischemia%E2%80%83through%E2%80%83targeting%E2%80%83FADD%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiochim%E2%80%83%0ABiophys%E2%80%83Acta%E2%80%83Mol%E2%80%83Basis%E2%80%83Dis%EF%BC%8C2024%EF%BC%8C1870%EF%BC%887%EF%BC%89%EF%BC%9A%0A167323%EF%BC%8E

45、%E2%80%83DU%E2%80%83L%20%EF%BC%8C%20LU%E2%80%83Y%20%EF%BC%8C%20WANG%E2%80%83J%20%EF%BC%8C%20et%E2%80%83al%20%EF%BC%8E%20L%20n%20c%20R%20N%20A%E2%80%83%0AKIFAP3-5%EF%BC%9A1%E2%80%83%20inhibits%E2%80%83%20epithelial-mesenchymal%E2%80%83%0Atransition%E2%80%83%20of%E2%80%83%20renal%E2%80%83tubular%E2%80%83%20cell%E2%80%83through%E2%80%83%20PRRX1%E2%80%83in%E2%80%83%0Adiabetic%E2%80%83nephropathy%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Biol%E2%80%83Toxicol%EF%BC%8C%0A2024%EF%BC%8C40%EF%BC%881%EF%BC%89%EF%BC%9A47%EF%BC%8E

46、%E2%80%83%20FU%E2%80%83W%EF%BC%8CTIAN%E2%80%83X%EF%BC%8CLIU%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ELong%E2%80%83%20noncoding%E2%80%83%0ARNA%E2%80%83PR11-387H17%EF%BC%8E6%E2%80%83as%E2%80%83a%E2%80%83potential%E2%80%83novel%E2%80%83diagnostic%E2%80%83%0Abiomarker%E2%80%83of%E2%80%83atherosclerotic%E2%80%83renal%E2%80%83artery%E2%80%83stenosis%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ARen%E2%80%83Fail%EF%BC%8C2021%EF%BC%8C43%EF%BC%881%EF%BC%89%EF%BC%9A1188-1197%EF%BC%8E

47、SU%E2%80%83P%E2%80%83P%EF%BC%8CLIU%E2%80%83D%E2%80%83W%EF%BC%8CZHOU%E2%80%83S%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EDown%02regulation%E2%80%83%20of%E2%80%83%20Risa%E2%80%83%20improves%E2%80%83%20podocyte%E2%80%83%20injury%E2%80%83%20by%E2%80%83%0Aenhancing%E2%80%83autophagy%E2%80%83in%E2%80%83diabetic%E2%80%83nephropathy%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMil%E2%80%83Med%E2%80%83Res%EF%BC%8C2022%EF%BC%8C9%EF%BC%881%EF%BC%89%EF%BC%9A23%EF%BC%8E

48、WANG%E2%80%83Z%EF%BC%8CLIU%E2%80%83Z%EF%BC%8CYANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EIdentification%E2%80%83of%E2%80%83%0Abiomarkers%E2%80%83and%E2%80%83pathways%E2%80%83in%E2%80%83hypertensive%E2%80%83nephropathy%E2%80%83%0Abased%E2%80%83on%E2%80%83the%E2%80%83ceRNA%E2%80%83regulatory%E2%80%83network%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83%0ANephrol%EF%BC%8C2020%EF%BC%8C21%EF%BC%881%EF%BC%89%EF%BC%9A476%EF%BC%8E

49、%E2%80%83%20NISHITA-HIRESHA%E2%80%83V%EF%BC%8CVARSHA%E2%80%83R%EF%BC%8CJAYASURIYA%E2%80%83%0AR%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83%20role%E2%80%83%20of%E2%80%83%20circRNA-miRNA-mRNA%E2%80%83%0Ainteraction%E2%80%83network%E2%80%83in%E2%80%83endothelial%E2%80%83dysfunction%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AGene%EF%BC%8C2023%EF%BC%88851%EF%BC%89%EF%BC%9A146950%EF%BC%8E

50、HUANG%E2%80%83J%E2%80%83G%EF%BC%8CTANG%E2%80%83X%EF%BC%8CWANG%E2%80%83J%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83%0Acircular%E2%80%83RNA%EF%BC%8CcircUSP36%EF%BC%8Caccelerates%E2%80%83endothelial%E2%80%83cell%E2%80%83%0Adysfunction%E2%80%83in%E2%80%83atherosclerosis%E2%80%83by%E2%80%83adsorbing%E2%80%83miR-637%E2%80%83%0Ato%E2%80%83enhance%E2%80%83WNT4%E2%80%83expression%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBioengineered%EF%BC%8C%0A2021%EF%BC%8C12%EF%BC%881%EF%BC%89%EF%BC%9A6759-6770%EF%BC%8E

51、%E2%80%83%20CHEN%E2%80%83W%EF%BC%8CXU%E2%80%83J%EF%BC%8CWU%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83%20potential%E2%80%83%20role%E2%80%83%0Aand%E2%80%83mechanism%E2%80%83of%E2%80%83circRNA%2FmiRNA%E2%80%83axis%E2%80%83in%E2%80%83cholesterol%E2%80%83synthesis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Biol%E2%80%83Sci%EF%BC%8C2023%EF%BC%8C19%EF%BC%889%EF%BC%89%EF%BC%9A%0A2879-2896%EF%BC%8E

52、%E2%80%83%20PAN%E2%80%83Z%EF%BC%8CLV%E2%80%83J%EF%BC%8CZHAO%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8ECi%20rcARCN%201%E2%80%83%0Aaggravates%E2%80%83atherosclerosis%E2%80%83by%E2%80%83regulating%E2%80%83HuR-mediated%E2%80%83%0AUSP31%E2%80%83mRNA%E2%80%83in%E2%80%83macrophages%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECardiovasc%E2%80%83%0ARes%EF%BC%8C2024%EF%BC%8C120%EF%BC%8813%EF%BC%89%EF%BC%9A1531-1549%EF%BC%8E

53、YANG%E2%80%83Z%EF%BC%8CHUANG%E2%80%83C%EF%BC%8CWEN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8ECircular%E2%80%83RNA%E2%80%83%0Acirc-FoxO3%E2%80%83attenuates%E2%80%83blood-brain%E2%80%83barrier%E2%80%83damage%E2%80%83by%E2%80%83%0Ainducing%E2%80%83autophagy%E2%80%83during%E2%80%83ischemia%2Freperfusion%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMol%E2%80%83Ther%EF%BC%8C2022%EF%BC%8C30%EF%BC%883%EF%BC%89%EF%BC%9A1275-1287%EF%BC%8E

54、YANG%E2%80%83L%EF%BC%8CHAN%E2%80%83B%EF%BC%8CZHANG%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8EExtracellular%E2%80%83%0Avesicle-mediated%E2%80%83%20delivery%E2%80%83%20of%E2%80%83%20circular%E2%80%83RNA%E2%80%83%20SCMH1%E2%80%83%0Apromotes%E2%80%83functional%E2%80%83%20recovery%E2%80%83in%E2%80%83%20rodent%E2%80%83and%E2%80%83nonhuman%E2%80%83%0Aprimate%E2%80%83ischemic%E2%80%83stroke%E2%80%83models%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirculation%EF%BC%8C%0A2020%EF%BC%8C142%EF%BC%886%EF%BC%89%EF%BC%9A556-574%EF%BC%8E

55、%E2%80%83%20CHEN%E2%80%83J%EF%BC%8CLI%E2%80%83X%EF%BC%8CLIU%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EBone%E2%80%83marrow%E2%80%83stromal%E2%80%83%0Acell-derived%E2%80%83exosomal%E2%80%83circular%E2%80%83RNA%E2%80%83improves%E2%80%83diabetic%E2%80%83%0Afoot%E2%80%83ulcer%E2%80%83wound%E2%80%83healing%E2%80%83by%E2%80%83activating%E2%80%83the%E2%80%83nuclear%E2%80%83factor%E2%80%83%0Aerythroid%E2%80%83%202-related%E2%80%83factor%E2%80%83%202%E2%80%83%20pathway%E2%80%83%20and%E2%80%83inhibiting%E2%80%83%0Aferroptosis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDiabet%E2%80%83Med%EF%BC%8C2023%EF%BC%8C40%EF%BC%887%EF%BC%89%EF%BC%9A%0Ae15031%EF%BC%8E

56、%E2%80%83%20LIU%E2%80%83J%EF%BC%8CZHANG%E2%80%83Y%EF%BC%8CLIU%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83%20single%E2%80%83%20dose%E2%80%83%0Aof%E2%80%83VEGF-A%E2%80%83circular%E2%80%83RNA%E2%80%83%20sustains%E2%80%83in%E2%80%83%20situ%E2%80%83long-term%E2%80%83%0Aexpression%E2%80%83%20of%E2%80%83%20protein%E2%80%83to%E2%80%83%20accelerate%E2%80%83%20diabetic%E2%80%83%20wound%E2%80%83%0Ahealing%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Control%E2%80%83Release%EF%BC%8C2024%EF%BC%88373%EF%BC%89%EF%BC%9A%0A319-335%EF%BC%8E

57、LIU%E2%80%83X%EF%BC%8CJIANG%E2%80%83L%EF%BC%8CZENG%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ECirc-%0A0000953deficiency%E2%80%83exacerbates%E2%80%83%20podocyte%E2%80%83injury%E2%80%83and%E2%80%83%0Aautophagy%E2%80%83%20disorder%E2%80%83%20by%E2%80%83targetingMir665-3p-Atg4bin%E2%80%83%0Adiabetic%E2%80%83nephropathy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAutophagy%EF%BC%8C2024%EF%BC%8C20%0A%EF%BC%885%EF%BC%89%EF%BC%9A1072-1097%EF%BC%8E

58、ZHANG%E2%80%83K%EF%BC%8CLI%E2%80%83Y%EF%BC%8CHUANG%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8EPiRNA%E2%80%83in%E2%80%83%0Acardiovascular%E2%80%83disease%EF%BC%9AFocus%E2%80%83on%E2%80%83cardiac%E2%80%83%20remodeling%E2%80%83%0Aand%E2%80%83cardiac%E2%80%83protection%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%20Cardiovasc%E2%80%83%20Transl%E2%80%83%0ARes%EF%BC%8C2023%EF%BC%8C16%EF%BC%884%EF%BC%89%EF%BC%9A768-777%EF%BC%8E

59、%E2%80%83%20HE%E2%80%83T%EF%BC%8CPU%E2%80%83J%EF%BC%8CGE%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EElevated%E2%80%83%20circulating%E2%80%83%0ALncRNA%E2%80%83NORAD%E2%80%83fosters%E2%80%83endothelial%E2%80%83cell%E2%80%83growth%E2%80%83and%E2%80%83%0Aaverts%E2%80%83ferroptosis%E2%80%83by%E2%80%83modulating%E2%80%83the%E2%80%83miR-106a%2FCCND1%E2%80%83%0Aaxis%E2%80%83in%E2%80%83CAD%E2%80%83patients%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESci%E2%80%83Rep%EF%BC%8C2024%EF%BC%8C14%0A%EF%BC%881%EF%BC%89%EF%BC%9A24223%EF%BC%8E

60、RAY%E2%80%83K%E2%80%83K%EF%BC%8CTROQUAY%E2%80%83R%E2%80%83P%E2%80%83T%EF%BC%8CVISSEREN%E2%80%83F%E2%80%83L%E2%80%83J%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8ELong-term%E2%80%83efficacy%E2%80%83and%E2%80%83%20safety%E2%80%83of%E2%80%83inclisiran%E2%80%83in%E2%80%83%0Apatients%E2%80%83with%E2%80%83high%E2%80%83cardiovascular%E2%80%83risk%E2%80%83and%E2%80%83elevated%E2%80%83LDL%E2%80%83%0Acholesterol%EF%BC%88ORION-3%EF%BC%89%EF%BC%9AResults%E2%80%83from%E2%80%83the%E2%80%83%204-year%E2%80%83%0Aopen-label%E2%80%83extension%E2%80%83of%E2%80%83the%E2%80%83ORION-1%E2%80%83trial%EF%BC%BBJ%EF%BC%BD%EF%BC%8ELancet%E2%80%83Diabetes%E2%80%83Endocrinol%EF%BC%8C2023%EF%BC%8C11%EF%BC%882%EF%BC%89%EF%BC%9A109-%0A119%EF%BC%8E

61、%E2%80%83%20ZHAN%E2%80%83L%EF%BC%8CCHEN%E2%80%83M%EF%BC%8CPANG%E2%80%83T%EF%BC%8Cet%E2%80%83al%EF%BC%8EAttenuation%E2%80%83of%E2%80%83%0APiwil2%E2%80%83induced%E2%80%83%20by%E2%80%83%20hypoxic%E2%80%83%20postconditioning%E2%80%83%20prevents%E2%80%83%0Acerebral%E2%80%83ischemic%E2%80%83injury%E2%80%83by%E2%80%83inhibiting%E2%80%83CREB2%E2%80%83promoter%E2%80%83%0Amethylation%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBrain%E2%80%83Pathol%EF%BC%8C2023%EF%BC%8C33%EF%BC%881%EF%BC%89%EF%BC%9A%0Ae13109%EF%BC%8E

62、SUN%E2%80%83H%EF%BC%8CLI%E2%80%83S%EF%BC%8CXU%E2%80%83Z%EF%BC%8Cet%E2%80%83al%EF%BC%8ESNHG15%E2%80%83is%E2%80%83a%E2%80%83negative%E2%80%83%0Aregulator%E2%80%83%20of%E2%80%83%20inflammation%E2%80%83%20by%E2%80%83%20mediating%E2%80%83%20TRAF2%E2%80%83%0Aubiquitination%E2%80%83in%E2%80%83stroke-induced%E2%80%83immunosuppression%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Neuroinflammation%EF%BC%8C2022%EF%BC%8C19%EF%BC%881%EF%BC%89%EF%BC%9A1%EF%BC%8E

63、ZONG%E2%80%83T%EF%BC%8CYANG%E2%80%83Y%EF%BC%8CZHAO%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EtsRNAs%EF%BC%9A%0ANovel%E2%80%83small%E2%80%83molecules%E2%80%83from%E2%80%83cell%E2%80%83function%E2%80%83and%E2%80%83regulatory%E2%80%83%0Amechanism%E2%80%83to%E2%80%83therapeutic%E2%80%83targets%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECell%E2%80%83Prolif%EF%BC%8C%0A2021%EF%BC%8C54%EF%BC%883%EF%BC%89%EF%BC%9Ae12977%EF%BC%8E

64、才振国，杨艳丽，李竹英，等．中医药调控心脏疾病中长链非编码RNA研究进展［J］．河北中医，2022，44（8）：1391-1396，1400．

65、周霞辉，罗晓欣，周曼丽，等．冠状动脉粥样硬化性心脏病血瘀证表观遗传学研究进展［J］．中国中医药信息杂志，2022，29（6）：148-152．

66、SU%E2%80%83W%EF%BC%8CLV%E2%80%83M%EF%BC%8CWANG%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8ETanshinone%E2%80%83%20IIA%E2%80%83%0Aalleviates%E2%80%83traumatic%E2%80%83brain%E2%80%83injury%E2%80%83by%E2%80%83reducing%E2%80%83ischemia%E2%80%92%0Areperfusion%E2%80%83via%E2%80%83the%E2%80%83miR-124-5p%2FFoxO1%E2%80%83axis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMediators%E2%80%83Inflamm%EF%BC%8C2024%EF%BC%882024%EF%BC%89%EF%BC%9A7459054%EF%BC%8E

67、%E2%80%83%20LI%E2%80%83Y%EF%BC%8CYE%E2%80%83Q%EF%BC%8CLI%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EExploring%E2%80%83the%E2%80%83mechanism%E2%80%83%0Aof%E2%80%83Taohong%E2%80%83Siwu%E2%80%83Decoction%E2%80%83in%E2%80%83treating%E2%80%83ischemic%E2%80%83stroke%E2%80%83%0Ainjury%E2%80%83via%E2%80%83the%E2%80%83circDnajc1%2FmiR-27a-5p%2FC1qc%E2%80%83signaling%E2%80%83%0Aaxis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPhytomedicine%EF%BC%8C2025%EF%BC%88136%EF%BC%89%EF%BC%9A156305%EF%BC%8E

68、%E2%80%83%20FROLDI%E2%80%83G%EF%BC%8CRAGAZZI%E2%80%83E%EF%BC%8ESelected%E2%80%83%20plant-derived%E2%80%83%0Apolyphenols%E2%80%83%20as%E2%80%83%20potential%E2%80%83%20therapeutic%E2%80%83%20agents%E2%80%83%20for%E2%80%83%0Aperipheral%E2%80%83artery%E2%80%83disease%EF%BC%9AMolecular%E2%80%83mechanisms%EF%BC%8C%0Aefficacy%E2%80%83and%E2%80%83safety%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMolecules%EF%BC%8C2022%EF%BC%8C27%0A%EF%BC%8820%EF%BC%89%EF%BC%9A7110%EF%BC%8E

69、%E5%80%AA%E8%8B%B1%E7%BE%A4%EF%BC%8C%E6%9D%8E%E5%B1%85%E4%B8%80%EF%BC%8C%E9%BB%84%E6%97%A5%E9%BE%99%EF%BC%8C%E7%AD%89%EF%BC%8E%E6%B0%94%E9%98%B4%E4%B8%A4%E8%99%9A%E5%A4%B9%E7%98%80%E5%9E%8B2%E5%9E%8B%E7%B3%96%E5%B0%BF%E7%97%85%E6%82%A3%E8%80%85%E5%A4%96%E5%91%A8%E8%A1%80LncRNA%E2%80%83TUG%E2%80%831%E4%B8%8E%E8%A1%80%E7%AE%A1%E7%97%85%E5%8F%98%E6%A0%87%E5%BF%97%E5%9B%A0%E5%AD%90%E7%9A%84%E7%9B%B8%E5%85%B3%E6%80%A7%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E8%BE%BD%E5%AE%81%E4%B8%AD%E5%8C%BB%E6%9D%82%E5%BF%97%EF%BC%8C2024%EF%BC%8C51%EF%BC%885%EF%BC%89%EF%BC%9A23-25%EF%BC%8E

70、ZHANG%E2%80%83Y%20%EF%BC%8C%20DENG%E2%80%83Y%20%EF%BC%8C%20YANG%E2%80%83Y%20%EF%BC%8C%20et%E2%80%83al%20%EF%BC%8E%0APoly%20sacc%20ha%20ri%20de%20s%E2%80%83%20f%20rom%E2%80%83%20De%20n%20d%20ro%20bi%20um%E2%80%83%20offici%20nale%E2%80%83%0Adelay%E2%80%83%20diabetic%E2%80%83%20kidney%E2%80%83%20disease%E2%80%83interstitial%E2%80%83fibrosis%E2%80%83%0Athrough%E2%80%83LncRNA%E2%80%83XIST%2FTGF-%CE%B21%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBiomed%E2%80%83%0APharmacother%EF%BC%8C2024%EF%BC%88175%EF%BC%89%EF%BC%9A116636%EF%BC%8E

71、LI%E2%80%83C%EF%BC%8CZHANG%E2%80%83S%EF%BC%8CCHEN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EFarnesoid%E2%80%83%20X%E2%80%83%0Areceptor%E2%80%83activation%E2%80%83inhibits%E2%80%83TGFBR1%2FTAK1-mediated%E2%80%83%0Avascular%E2%80%83inflammation%E2%80%83and%E2%80%83calcification%E2%80%83via%E2%80%83miR-135a-%0A5p%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECommun%E2%80%83Biol%EF%BC%8C2020%EF%BC%8C3%EF%BC%881%EF%BC%89%EF%BC%9A327%EF%BC%8E

1、国家自然科学基金（82474479）；辽宁省科技厅面上项目（2024-MSLH-312）；辽宁省教育厅青年项目（JYTQN2023470）；辽宁中医药大学项目（2021LZY018）；辽宁省科技厅面上项目（2024-MSLH-306）()